. Heart-type fatty acid-binding protein reciprocally regulates glucose and fatty acid utilization during exercise.
LONG-CHAIN FATTY ACID (LCFA) transport across phospholipid membranes is facilitated by a number of fatty acid-binding proteins, including fatty acid translocase (FAT/CD36), fatty acid transport protein (FATP), and fatty acid-binding protein (FABP) in the plasma membrane (FABP pm ) (5, 6) . Once across cellular membranes, LCFA are tightly bound to cytosolic FABPs. In cardiac and skeletal muscle, heart-type cytosolic FABP (H-FABP) is present in abundance, representing 2-5% of total cytosolic protein (22) . H-FABP functions to increase LCFA solubility, facilitate diffusion, and protect against LCFA toxicity. It also mediates LCFA trafficking by targeting LCFA to specific triacylglycerol depots, the maintenance of phospholipid pool mass, and phospholipid acyl chain composition (17, 23) . In this capacity, H-FABP may influence not only LCFA metabolism but also the selection and utilization of other substrates, namely glucose. This is evident in types 1 and 2 diabetes, where there is increased H-FABP expression, presumably due to a greater reliance on fatty acid utilization (2, 12) .
Despite the diverse role of H-FABP in mediating LCFA metabolism, a heterozygous germ line reduction of H-FABP (H-FABP ϩ/Ϫ ) has no observable phenotype in the sedentary mouse (11, 15) . This suggests that 50% of the protein is sufficient to meet basal metabolic demands. In contrast, a homozygous germ line deletion of H-FABP (H-FABP Ϫ/Ϫ ) results in partial, but not complete, abolishment of LCFA utilization (3, 11) . The most marked perturbation is in cardiac muscle, where there is a greater reliance on glucose and the development of cardiac hypertrophy. Skeletal muscle has qualitatively similar, but quantitatively lesser, effects compared with the heart, with increases in glucose oxidation and decreases in LCFA utilization (4) . During contraction, isolated soleus muscle from H-FABP Ϫ/Ϫ mice maintains the capacity to increase LCFA uptake, esterification, and oxidation in response to electrical stimulation (4) . However, these parameters are still reduced compared with muscle from wild-type (WT) littermates. Despite their ability to increase LCFA utilization in response to electrical stimulation, H-FABP Ϫ/Ϫ are intolerant to prolonged exercise (3). Explanations for this exercise intolerance are not known but are likely related to impairments in LCFA utilization in both cardiac and skeletal muscle (11) .
The aim of the present study was to determine the role of H-FABP on tissue-specific and whole body substrate utilization when metabolic demands are elevated by exercise. Although previous studies have explored the effects of H-FABP Ϫ/Ϫ in vitro, the role of reduced levels of H-FABP (H-FABP ϩ/Ϫ ) in the context of the whole animal and its physiological function are incompletely understood. Using exercise as a phenotyping tool along with glucose and LCFA isotopic analogs to simultaneously assess substrate utilization, we demonstrate that H-FABP influences substrate utilization and that H-FABP Ϫ/Ϫ mice have reduced exercise tolerance due to increased reliance on glucose and the development of overt hypoglycemia.
METHODS
Mouse maintenance and genotyping. All procedures were approved by the Vanderbilt University Animal Care and Use Committee. Mice were produced on a 129/Balb/c background and were subsequently backcrossed for at least seven generations to C57BL/6J (3). This results in the absence of H-FABP in homozygous mice and a 50% reduction in heterozygous mice (3). Mice carrying the disrupted H-FABP allele (H-FABP ϩ/Ϫ ) were subsequently bred, and, after a 3-wk weaning period, littermates were separated by sex and maintained in microisolator cages. Genotyping for the H-FABP germ line deletion was performed on genomic DNA obtained from a tail biopsy with the polymerase chain reaction, as previously described (4) . Mice were fed a standard chow diet ad libitum and were studied at ϳ4 mo of age. Experiments were performed on both male (M) and female (F) mice. Numbers of male and female mice per group are as follows: WT (n ϭ 4 M/4 F), H-FABP ϩ/Ϫ (n ϭ 4 M/4 F), and H-FABP Ϫ/Ϫ (n ϭ 3 M/4 F).
Surgical procedures. The surgical procedures were the same as those previously described (10) . Mice were anesthetized with pentobarbitol sodium (70 mg/kg body wt). The left common carotid artery was catheterized for sampling with a catheter consisting of PE-10 and 0.025-in. OD Silastic tubing. The right jugular vein was catheterized for infusions with a Silastic catheter (0.025 in. OD). The free ends of the catheters were tunneled under the skin to the back of the neck, where they were attached via stainless steel connectors to tubing made of Micro-Renathane (0.033 in. OD), which were exteriorized and sealed with stainless steel plugs. Lines were flushed daily with ϳ20 l of saline containing 200 U/ml heparin and 5 mg/ml ampicillin. Animals were individually housed after surgery and body weight was recorded daily.
Isotopic analogs. In vivo exercise experiments. Mice were acclimated to treadmill running with a single 10-min bout of exercise (0.5-0.6 mph, 0% grade) ϳ48 h before the experimental protocol. Experiments were conducted after a postoperative recovery period of ϳ7 days, as previously described (13) . The recovery period was sufficient for body weight to be restored within 10% of presurgery body weight. On the day of the study, conscious, unrestrained mice were placed in an ϳ1-liter plastic container lined with bedding and fasted for 5 h. Approximately 1 h before an experiment, Micro-Renathane (0.033 in. OD) tubing was connected to the catheter leads and infusion syringes. Mice were then placed in the treadmill and allowed to acclimate before exercise (1 h). After this, a baseline arterial blood sample (150 l) was drawn for the measurement of arterial blood glucose, hematocrit, plasma insulin, and nonesterified fatty acids (NEFAs). The remaining red blood cells were washed with 0.9% heparinized saline and reinfused. Mice then exercised on a motorized treadmill (0.6 mph, 0% grade) for 30 min. At t ϭ 5 min, a 12-Ci bolus of [2- 3 H]DG and a bolus (21- (18) . Briefly, plasma and infusates were counted for [ 125 I]BMIPP with a Beckman Gamma 5500 counter (Beckman Instruments, Fullerton, CA). After this, the plasma samples were deproteinized in 100 l of 0.06 N Ba(OH) 2 and 100 l of 0.06 N Zn(SO)4 and subsequently centrifuged. The supernatant (100 l) was extracted and diluted in 900 l of H 2O.
3 H radioactivity was counted after addition of fluor (10 ml of Ultimate Gold; Packard Bioscience, Boston, MA) by use of a Packard Tri-Carb 2900TR Liquid Scintillation Analyzer (PerkinElmer, Boston, MA). Similarly, 125 I radioactivity was determined in tissues before they were homogenized in 2 ml of 0.5% perchloric acid and centrifuged for 20 min. Supernatants (1.5 ml) were then neutralized using 5 M KOH, and 250 l were determined by liquid scintillation counting (TRI-CARB 2900TR; Packard, Meriden, CT) with Ultima Gold (Packard) as scintillant. The relationship between gamma-radioactivity and beta-emissions for the specific counters was previously determined and used to correct 3 H radioactivity for beta-emissions originating from 125 I radioactivity (18 (10, 13) . The relationships are defined as follows:
The subscripts p and m refer to concentrations in arterial plasma and muscle, respectively. The measurement of R g has been described earlier (10, 13 (8, 18) . To determine whole body metabolic clearance rates (MCR) for glucose and LCFA from the plasma, the following equations were used. D represents total dose of the tracer normalized to radioactivity in the infusate. (Fig. 2) . ) were measured in soleus, gastrocnemius (Gastroc), superficial vastus lateralis (SVL), and heart. *Significant difference (P Ͻ 0.05) from WT. †Significant difference (P Ͻ 0.05) from H-FABP ϩ/Ϫ . To establish a dose responsiveness between substrate utilization and H-FABP, a linear regression analysis was performed, and the linear regression coefficient (r 2 ) is reported. ) in soleus, Gastroc, SVL, and heart during 30 min of treadmill exercise in conscious, unrestrained mice. *Significant difference (P Ͻ 0.05) from WT. †Significant difference (P Ͻ 0.05) from H-FABP ϩ/Ϫ . To establish a dose responsiveness between substrate utilization and H-FABP, linear regression analysis was performed, and r 2 is reported. 
DISCUSSION
The studies performed herein show, using a novel chronically catheterized mouse model, that H-FABP has an important role in determining the relative usage of LCFA and glucose in working muscle. Using exercise to accelerate metabolism in WT, H-FABP ϩ/Ϫ and H-FABP Ϫ/Ϫ mice, we show that Ն50% of this protein is necessary to maintain LCFA flux. Both heterozygous and null mutations had reciprocal effects on glucose and LCFA utilization when metabolic demands were elevated in vivo. These effects were evident in the whole animal as well as in heart and individual muscles excised from mice.
Analysis of cardiac and skeletal muscles demonstrate reduced rates of LCFA and a compensatory increase in glucose utilization with declining H-FABP levels. In H-FABP Ϫ/Ϫ mice, R f was reduced in all muscles with the exception of the SVL, a muscle comprising highly glycolytic fibers (1). Reductions in R f were greatest in the soleus and heart of H-FABP Ϫ/Ϫ mice, with reductions of ϳ75 and ϳ80%, respectively, compared with WT mice. This result is consistent with previous studies on H-FABP demonstrating that the effects of H-FABP ablation are most pronounced in these two tissues (3, 4, 17) . Albeit present to a lesser extent, reductions in R f were also evident in the heart and soleus of H-FABP ϩ/Ϫ mice. This is a novel finding and demonstrates that Ͼ50% of H-FABP is necessary to accommodate increased LCFA flux during exercise. To compensate for decreases in LCFA uptake, H-FABP ϩ/Ϫ and H-FABP Ϫ/Ϫ mice increase their reliance on glucose. The greatest compensation was in the heart, a finding not unexpected considering the heart normally derives 60 -80% of its energy from LCFA (14) . Similar impacts of H-FABP were also noted for whole body MCR. In response to exercise, H-FABP Ϫ/Ϫ mice developed overt hypoglycemia due to a decreased LCFA capacity. This finding explains the results of previous studies showing H-FABP Ϫ/Ϫ mice to be exercise intolerant (3) . Due to the sharp fall in blood glucose and the mild exercise intensity used in the experimental protocol (ϳ70% O 2 consumption), it appears that the majority of glucose was derived from blood glucose and not glycogen. Binas et al. (4) have characterized glycogen in H-FABP Ϫ/Ϫ mice and shown that resting soleus muscle from H-FABP Ϫ/Ϫ mice contains ϳ34% less glycogen compared with WT mice; however, following electrical stimulation of muscles, the absolute amount of glycogen utilized did not differ between WT and H-FABP Ϫ/Ϫ mice (4). In the present study, we show that LCFA utilization during exercise was compromised in H-FABP Ϫ/Ϫ mice but not completely abolished. Detailed phenotyping of these mice reveals normal expression and tissue content of other FABPs, including FAT/CD36 and FABP pm (4, 15, 19) . However, it is possible that reduced levels of H-FABP negatively impact exerciseinduced sarcolemmal recruitment of these proteins, resulting in the impaired fatty acid transport. To compensate for reduced levels of H-FABP, null mice selectively increase their mitochondrial density in subsarcolemmal space (4) . It was hypothesized that this adaptation limits the diffusion distance of LCFA from the cytosolic membrane to mitochondria, thus enabling continued LCFA metabolism in the absence of H-FABP (4). This finding also suggests that H-FABP functions to target LCFA to the mitochondria. In agreement with this hypothesis, Murphy et al. (17) have shown that H-FABP may direct incoming LCFA to storage, oxidation, or esterification depending on the type of fatty acid. Specifically, in resting anesthetized mice, H-FABP Ϫ/Ϫ resulted in an ϳ52% decline in 20:4 n-6 uptake and an ϳ40% reduction in 16:0 compared with WT littermates (17) . Additionally, H-FABP Ϫ/Ϫ preferentially impaired LCFA targeting of 16:0 destined to ␤-oxidation to a greater extent compared with esterification. This led the authors to conclude that H-FABP is an important determinant of the metabolic fate of individual fatty acids.
Results of the present study corroborate previous findings showing that normal levels of H-FABP have a fundamental, but not limiting, role in regulating LCFA utilization at rest (4, 15) . However, we show that a full complement of H-FABP is required for augmented rates of LCFA utilization in cardiac and skeletal muscle with exercise. This may be one reason that the protein is expressed in such abundance, a finding that was unclear from previous in vitro studies. It may also explain why levels of H-FABP are elevated in situations wherein LCFA flux is augmented, such as diabetes, chronic exercise, and diets supplemented with (-3) polyunsaturated fatty acids (2, 7, 12, 20) . Although H-FABP may not limit basal metabolism, it compromises substrate utilization when metabolic demands are increased. Given this, reducing H-FABP may be a plausible pharmacological target in the treatment of pathophysiological states wherein glucose utilization is impaired such as type 2 diabetes. Indeed, recent studies have shown that a heterozygous reduction in H-FABP is sufficient to normalize elevated blood glucose levels caused by high-fat feeding (21) . This increased sensitivity to insulin was due to the same phenomenon observed in the present study, a decreased capacity for LCFA utilization and increased reliance on glucose. However, the present results also caution that reducing H-FABP may lead to an increased risk of hypoglycemia in response to prolonged or intense exercise.
During the experimental protocol, all mice performed 30 min of treadmill exercise at 0.6 mph, which represents ϳ70% of maximal oxygen consumption (9) . Although the absolute amount of work performed by each animal was identical, the relative workload may be different between genotypes. Given this, it is possible that H-FABP ϩ/Ϫ and H-FABP Ϫ/Ϫ mice exercised at a higher relative exercise intensity compared with WT animals, resulting in increased rates of glucose utilization. Further exercise testing of the H-FABP mice will be needed to resolve this issue. Despite the diminished exercise-induced R f in H-FABP Ϫ/Ϫ and H-FABP ϩ/Ϫ mice, LCFA levels still fell to the same level. An interesting finding from the present study is that, despite reduced R f in H-FABP ϩ/Ϫ and H-FABP Ϫ/Ϫ mice, plasma LCFA (ϳ1 mM) fell to the same levels. Considering the reduced R f , it would have been reasonable to expect that LCFA levels would remain higher in H-FABP ϩ/Ϫ and H-FABP Ϫ/Ϫ mice. This result implies that there may be a compensatory mechanism for a deficit in H-FABP, whereby either the capacity for lipolysis is reduced or reesterification of LCFA is increased.
In conclusion, we demonstrate that, in vivo, reductions in H-FABP result in reciprocal effects on both tissue-specific and whole body LCFA and glucose utilization during exercise. Although FABP ϩ/Ϫ mice have no discernible phenotype at rest, exercise reveals that Ͼ50% of this protein is required to accommodate high rates of LCFA flux into cardiac and skeletal muscle. This finding further elucidates the role of H-FABP and explains why this protein may be upregulated in metabolic situations wherein rates of LCFA utilization are elevated.
